Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Oric Pharmaceuticals (ORIC) and Irhythm Technologies (IRTC)

Tipranks - Tipranks - Tue Apr 14, 7:06AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Revolution Medicines (RVMD), Oric Pharmaceuticals (ORIC) and Irhythm Technologies (IRTC) with bullish sentiments.

Claim 30% Off TipRanks

Revolution Medicines (RVMD)

J.P. Morgan analyst Brian Cheng maintained a Buy rating on Revolution Medicines today and set a price target of $125.00. The company’s shares closed last Friday at $96.43.

According to TipRanks.com, Cheng is a 2-star analyst with an average return of 0.5% and a 44.6% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Monte Rosa Therapeutics, and Crispr Therapeutics AG. ;'>

Currently, the analyst consensus on Revolution Medicines is a Strong Buy with an average price target of $141.67, a 46.0% upside from current levels. In a report issued on April 1, LifeSci Capital also assigned a Buy rating to the stock with a $144.00 price target.

See the top stocks recommended by analysts >>

Oric Pharmaceuticals (ORIC)

In a report released today, Anupam Rama from J.P. Morgan maintained a Buy rating on Oric Pharmaceuticals. The company’s shares closed last Friday at $10.15.

According to TipRanks.com, Rama is a 5-star analyst with an average return of 21.5% and a 50.8% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Ultragenyx Pharmaceutical, and Maze Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oric Pharmaceuticals with a $21.33 average price target, a 105.5% upside from current levels. In a report issued on April 1, Evercore ISI also maintained a Buy rating on the stock with a $25.00 price target.

Irhythm Technologies (IRTC)

BTIG analyst Marie Thibault maintained a Buy rating on Irhythm Technologies today and set a price target of $185.00. The company’s shares closed last Friday at $115.24.

According to TipRanks.com, Thibault has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.5% and a 31.6% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Orchestra BioMed Holdings, and Edwards Lifesciences. ;'>

Irhythm Technologies has an analyst consensus of Strong Buy, with a price target consensus of $195.36, representing a 66.1% upside. In a report issued on April 7, Citi also assigned a Buy rating to the stock with a $155.00 price target.

Read More on RVMD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).